In fiscal 2025, which ended Jan 3, 2026, Usana Health Sciences, Inc. reported revenue of $925.3 million. Net income was $10.8 million, a profit margin of 1.2%. Operating income came to $37.4 million, an operating margin of 4.0%. Diluted earnings per share were $0.58. Over the twelve months ended Jul 4, 2026, revenue was $913.4 million and the net loss was $22.2 million. Across the 8 fiscal years shown, revenue shrank from $1.2 billion in fiscal 2018 to $925.3 million in fiscal 2025, about 3.5% a year.
USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.
| Line |
FY 2026
Jul 4, 2026
|
FY 2025
Jan 3, 2026
|
FY 2023
Dec 28, 2024
|
FY 2023
Dec 30, 2023
|
FY 2022
Dec 31, 2022
|
FY 2022
Jan 1, 2022
|
FY 2020
Jan 2, 2021
|
FY 2019
Dec 28, 2019
|
FY 2018
Dec 29, 2018
|
FY 2017
Dec 30, 2017
|
FY 2016
Dec 31, 2016
|
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
913
|
925
|
855
-28.0%
|
921
-22.4%
|
999
|
1,186
|
1,135
+7.0%
|
1,061
-10.8%
|
1,189
|
—
|
—
|
| Cost of revenue |
206
|
201
|
161
-26.0%
|
177
-18.9%
|
194
|
218
|
209
+11.5%
|
188
-6.6%
|
201
+11.9%
|
179
-0.4%
|
180
+12.8%
|
| Gross profit |
707
|
724
|
693
-28.4%
|
744
-23.2%
|
805
|
969
|
926
+6.0%
|
873
-11.6%
|
989
+13.9%
|
868
+5.1%
|
826
+8.8%
|
| Research and development |
—
|
11
|
12
+4.1%
|
11
+3.0%
|
12
|
11
|
11
+3.6%
|
10
+0.2%
|
10
+14.4%
|
9
+1.2%
|
9
+37.7%
|
| Selling, general and administrative |
335
|
337
|
263
-5.7%
|
257
-7.9%
|
262
|
279
|
261
-2.4%
|
268
-2.7%
|
275
+3.8%
|
265
+13.2%
|
234
+12.1%
|
| Restructuring and impairment |
—
|
6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Operating income |
-1
|
37
|
66
-61.0%
|
93
-45.3%
|
108
|
170
|
176
+20.7%
|
146
-22.4%
|
188
+42.1%
|
133
-4.4%
|
139
-2.1%
|
| Interest income |
2
|
2
|
11
+350.1%
|
10
+283.2%
|
4
|
3
|
3
-46.1%
|
5
+6.3%
|
4
+102.6%
|
2
+47.6%
|
1
+32.6%
|
| Interest expense |
0
|
1
|
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Other non-operating income (expense) |
2
|
3
|
-1
+49.7%
|
0
+100.3%
|
-3
|
-2
|
-1
-70.4%
|
-0
+72.9%
|
-1
-41033.3%
|
-0
+99.7%
|
-1
-535.6%
|
| Pretax income |
3
|
42
|
76
-55.3%
|
102
-40.0%
|
109
|
171
|
178
+18.2%
|
150
-21.4%
|
192
+42.2%
|
135
-2.8%
|
139
-2.8%
|
| Income tax |
32
|
30
|
34
-36.7%
|
39
-28.6%
|
39
|
54
|
53
+6.6%
|
50
-23.5%
|
65
-9.5%
|
72
+87.2%
|
39
-19.6%
|
| Net income |
-22
|
11
|
42
-63.9%
|
64
-45.2%
|
69
|
117
|
125
+24.0%
|
101
-20.4%
|
126
+101.8%
|
63
-37.5%
|
100
+5.7%
|
| Basic EPS |
-1.21
|
0.58
|
2.20
-61.9%
|
3.31
-42.7%
|
3.60
|
5.78
|
5.89
+32.7%
|
4.44
-15.3%
|
5.24
+103.9%
|
2.57
-37.9%
|
4.14
+11.3%
|
| Diluted EPS |
-1.20
|
0.58
|
2.19
-61.8%
|
3.30
-42.4%
|
3.59
|
5.73
|
5.86
+32.9%
|
4.41
-13.9%
|
5.12
+102.4%
|
2.53
-36.6%
|
3.99
+11.1%
|
| Weighted average shares, basic |
18
|
19
|
19
-5.2%
|
19
-4.4%
|
19
|
20
|
21
-6.6%
|
23
-6.1%
|
24
-1.0%
|
24
+0.7%
|
24
-5.0%
|
| Weighted average shares, diluted |
18
|
19
|
19
-5.8%
|
19
-4.9%
|
19
|
20
|
21
-6.8%
|
23
-7.4%
|
25
-0.3%
|
25
-1.4%
|
25
-5.0%
|
| Other measures | |||||||||||
| Depreciation and amortization |
32
|
33
|
13
-2.6%
|
13
-2.6%
|
13
|
13
|
14
-6.8%
|
15
-12.5%
|
17
+4.5%
|
16
+19.5%
|
13
+35.1%
|
| EBITDA |
31
|
70
|
79
-56.9%
|
106
-42.3%
|
121
|
183
|
190
+18.2%
|
161
-21.6%
|
205
+38.1%
|
149
-2.3%
|
152
+0.3%
|
| Interest coverage |
-2.62x
|
44.46x
|
236.03x
|
331.21x
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Margins | |||||||||||
| Gross margin |
77.45%
|
78.29%
|
81.13%
|
80.82%
|
80.58%
|
81.63%
|
81.57%
|
82.33%
|
83.12%
|
—
|
—
|
| Operating margin |
-0.12%
|
4.05%
|
7.76%
|
10.11%
|
10.78%
|
14.34%
|
15.55%
|
13.78%
|
15.84%
|
—
|
—
|
| Pretax margin |
0.28%
|
4.49%
|
8.94%
|
11.12%
|
10.88%
|
14.38%
|
15.68%
|
14.19%
|
16.10%
|
—
|
—
|
| Profit margin |
-2.43%
|
1.16%
|
4.92%
|
6.93%
|
6.94%
|
9.82%
|
10.99%
|
9.48%
|
10.61%
|
—
|
—
|
| EBITDA margin |
3.43%
|
7.56%
|
9.25%
|
11.48%
|
12.08%
|
15.44%
|
16.77%
|
15.17%
|
17.25%
|
—
|
—
|
| Effective tax rate |
1,253.35%
|
72.36%
|
44.91%
|
37.74%
|
36.15%
|
31.73%
|
29.94%
|
33.20%
|
34.09%
|
53.55%
|
27.80%
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.
New to this? Read How to Read an Income Statement, With a Real Example.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- USNA (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- UT
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 896264
- Former names
- USANA INC (until Apr 27, 2000)
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.